# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Marilyn Monroe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML002-SYN
- Date: 2026-06-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Joanna Whitlock, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Transvaginal ultrasound result and gynecology consultation the same day. **S**

## History of present illness

Ms. Monroe returns nine days after her first visit, on the morning of her transvaginal ultrasound, and is seen the same day by Dr. Okoye of gynecology. She started the continuous combined pill and naproxen after the first visit and has had no bleeding yet; she had one day of nausea on the pill, which passed. She has not taken diphenhydramine and has slept a little better with the sleep routine. Her gonorrhea and chlamydia tests and urinalysis from the first visit were negative. She has had her first session with the behavioral health clinician. She asks whether she will need an operation, and whether this will stop her from having children. She has had no thoughts of suicide or self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | Continuous combined pill and naproxen for nine days; no bleeding |
| Pain | Pelvic ache on most days, less than before |
| First-visit tests | Gonorrhea, chlamydia and urinalysis negative |
| Sleep | No diphenhydramine; a little better |
| Her questions | Surgery, and whether she can have children |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | One day of nausea on starting the pill; no bowel pain this week |
| Genitourinary | Positive | Low pelvic ache on most days; no bleeding or urinary symptoms |
| Neurological | Negative | No headaches or visual aura |
| Psychiatric | Positive | Still low but hopeful about the plan; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Naproxen 500 mg oral tablet, one tablet by mouth twice daily with food, from two days before an expected bleed until the third day, and for pain flares; no more than 10 days a month **S**
- Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg oral tablet, one tablet by mouth daily, taken continuously without a pill-free week **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 56.2 kg; BMI 20.4 kg/m². All vital signs are synthetic.

Anti-Mullerian hormone: 2.6 ng/mL. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 110/70, pulse 74; weight 56.2 kg |
| Abdomen | Soft; mild left lower quadrant tenderness; no mass |
| Pelvic | Examined by Dr. Okoye: tender, slightly fixed retroverted uterus; fullness and tenderness in the left adnexa; thickened, tender left uterosacral ligament; no nodule felt in the rectovaginal septum |
| Psychiatric | Anxious about fertility; organized; tearful briefly; no psychotic features |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Endometriosis with a left ovarian endometrioma** (N80.102). Transvaginal ultrasound today shows a 3.4 by 2.9 cm cyst in the left ovary with uniform ground-glass contents and no solid parts or internal blood flow, typical of an endometrioma; the left ovary lies against the back of the uterus; the bowel slides freely behind the uterus and no deep nodule of the bowel, rectovaginal septum or bladder is seen; the uterus is normal in size, without signs of adenomyosis; antral follicles 9 on the right and 6 on the left. With her symptoms and examination this establishes endometriosis without surgery. Dr. Okoye advises continuing medical treatment, keeping surgery in reserve, and avoiding repeated ovarian surgery. Anti-Mullerian hormone 2.6 ng/mL, in the typical range for her age. **S**
   - Continue the continuous combined pill and naproxen as needed.
   - Repeat transvaginal ultrasound in about four months.
   - Surgery only if pain does not respond, the cyst grows, or imaging changes.
   - Fertility plan: stop the pill when she wants to conceive, after a preconception visit; reproductive endocrinology referral if not pregnant after six months.
2. **Severe painful periods with pelvic pain, suspected endometriosis** (N94.6). Superseded by the diagnosis of endometriosis today. **S**
   - Problem resolved.
3. **Major depressive disorder, single episode, moderate** (F32.1). Therapy started. Safety reviewed: no thoughts of suicide or self-harm; the safety plan and the 988 Suicide & Crisis Lifeline are in her phone. **S**
   - Weekly cognitive behavioral therapy for the first month.
   - PHQ-9 and GAD-7 in about four weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Pelvic pain score (0 to 10), pain with intercourse and bowel movements, and missed working days | Every visit | Completed today | Ache on most days, less than before; no bowel pain this week; no missed work since the first visit |
| Self-management | Bleeding pattern on continuous suppression | Every visit | Completed today | No bleeding in nine days |
| Medication safety | Combined pill: adherence, side effects, and reasons to stop estrogen (migraine with aura, high blood pressure, clot symptoms, smoking) | Every visit, with blood pressure | Completed today | Taken daily; one day of nausea; blood pressure 110/70; no migraine with aura, clot symptoms or smoking |
| Medication safety | Naproxen: days used each month, and stomach or kidney symptoms | Every visit | Completed today | Naproxen on four days, with food; no stomach pain |
| Medication safety | No opioid, benzodiazepine, or sleep-medicine accumulation; prescription monitoring program | At the start, then every visit while pain is active | Completed today | No opioid or sedative since the first visit; diphenhydramine stopped; the prescription monitoring program was checked at the first visit |
| Imaging | Transvaginal ultrasound: endometrioma size and deep disease | At diagnosis; repeat at about four months on medical treatment, then yearly or if symptoms change | Completed today | 3.4 by 2.9 cm typical left endometrioma; no deep nodules; no adenomyosis |
| Laboratory | CA-125 | Not used to diagnose endometriosis | Not indicated | The ESHRE guideline advises against CA-125 for diagnosis; the ultrasound features are typical of an endometrioma |
| Laboratory | Ovarian reserve (anti-Mullerian hormone) | For fertility counseling and before any ovarian surgery | Completed today | 2.6 ng/mL, typical for her age; antral follicles 9 right and 6 left |
| Examination | Pelvic examination | At diagnosis, and when pain persists or changes | Completed today | Left adnexal and uterosacral tenderness; no rectovaginal nodule |
| Referral | Surgical evaluation (laparoscopic excision) | If pain does not respond to medical treatment, the cyst grows, or imaging is atypical | Completed today | Discussed by Dr. Okoye; not needed now; kept in reserve |
| Self-management | Pregnancy intention and fertility plan | Every visit | Completed today | Wants a pregnancy in about a year; the fertility plan agreed today |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Up to date | PHQ-9 12 nine days ago; next in about four weeks |
| Survey | Anxiety measure (GAD-7) | At diagnosis and with each depression measure | Up to date | GAD-7 8 nine days ago |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; leftover medicines returned to a pharmacy |
| Self-management | Cognitive behavioral therapy engagement | Weekly for the first month, then every two weeks | Completed today | First session done |
| Self-management | Sleep without sedatives | Every visit | Completed today | Regular bedtime; no diphenhydramine |

## Goal progress

- Worst pelvic pain 3 of 10 or less, and no missed working days for pain, by four months. In progress; target 2026-10-26. **S**
- No opioid, benzodiazepine or sleep-medicine prescription, and naproxen on 10 days a month or fewer. In progress; target 2026-10-26. **S**
- PHQ-9 score below 5 by four months. In progress; target 2026-10-26. **S**
- A written plan for when and how to try for a pregnancy, made with her before the four-month visit. In progress; target 2026-10-26. **S**

## Guideline basis

- Practice Bulletin No. 114: Management of Endometriosis (2010), American College of Obstetricians and Gynecologists (Obstetrics and Gynecology)
- ESHRE guideline: endometriosis (2022), European Society of Human Reproduction and Embryology (Human Reproduction Open)
- Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218 (2020), American College of Obstetricians and Gynecologists (Obstetrics and Gynecology)
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Behavioral health weekly. Preventive visit in about eight weeks. Endometriosis review in about three months with the pain score, PHQ-9 and GAD-7, and a repeat ultrasound at about four months. **S**
- Next scheduled visit 2026-08-17: periodic adult preventive visit with pregnancy planning. **S**
